Roche’s Tecentriq improves OS in first-line lung cancer
pharmafile | March 26, 2018 | News story | Research and Development, Sales and Marketing | Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq
Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, in addition to carboplatin and paclitaxel, was able to improve overall survival (OS) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC).
Though the exact data was not revealed as to how long OS was improved by, Roche announced that it was “significantly longer” when compared with just Avastin, alongside carboplatin and paclitaxel.
The data joins the previous announcement on benefits to progression-free survival, with a reduced risk of disease worsening or death by 38% compared with the previously mentioned course of treatment.
Combined, the data of PFS and OS benefit should see Tecentriq gain approval for its use in the first-line setting; Roche revealed that it would submit the additional data on OS to the FDA and EMA to support its application for first-line use.
According to analysts, Tecentriq’s use in this market could see it reap peak sales in the area of up to $5 billion and a potential $1.2 billion this year alone.
“We are pleased that the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,” said Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “These results add to the growing body of evidence supporting the role of combining Tecentriq with Avastin. We will submit these additional data to global health authorities and hope to bring this potential treatment option to patients as soon as possible.”
Roche had also studied Tecentriq without Avastin in the combination but interim results showed that OS was not improved, as a result. However, the company will continue the study for final analysis.
The new data adds to positive data that was revealed in advanced squamous NSCLC, which showed improvement to PFS, though it didn’t yet show the same benefits to OS.
Ben Hargreaves
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …
